26 January 2024
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine" or the "Company")
Grant of Share
Options
Canadian life sciences company,
Ondine Biomedical Inc., (AIM: OBI) announces that on 25 January
2024 ("Grant Date") it awarded a total of 11,950,000 stock options
("Options") to subscribe for new common shares in the Company. This
strategic move aligns with the Company's Option Plan, emphasizing
the commitment to attracting, retaining, and inspiring key talent
within its workforce, including employees, directors, advisory
board members, and key consultants.
In the period since 30 June 2023,
4,355,000 options have naturally expired or been forfeited.
Following the above grant of Options, Ondine Biomedical now has a
total of 15,640,000 outstanding Options in issue, equivalent to
6.9% of the Company's current issued share capital.
The distribution of Options to
Persons Discharging Managerial Responsibilities ("PDMR") is as
follows:
PDMR
|
Position
|
Options granted
|
Exercise price
|
Total options now held
|
Carolyn Cross
|
Executive Director
|
2,000,000
|
9p
|
2,075,000
|
Nicolas Loebel
|
Executive Director
|
3,500,000
|
9p
|
3,575,000
|
Joseph P. Errico
|
Chief Financial Officer
|
3,000,000
|
9p
|
3,000,000
|
Jean Charest
|
Chairman
|
40,000
|
9p
|
140,000
|
Craig Tooman
|
Non-Executive Director
|
25,000
|
9p
|
175,000
|
Michael Farrar
|
Non-Executive Director
|
25,000
|
9p
|
175,000
|
Jean Duvall
|
Non-Executive Director
|
25,000
|
9p
|
75,000
|
Simon Sinclair
|
Chief Medical Officer
|
150,000
|
9p
|
200,000
|
Junaid Bajwa
|
Non-Executive Director
|
25,000
|
9p
|
75,000
|
The Options have an exercise price of 9p, being the share price at
which new common shares were issued in connection with the
Company's fundraising announced on 30 November 2023. The Options
vest evenly over a period of 3 years from the Grant Date, with a
third vesting on each of the three successive anniversaries of the
Grant Date, and can be exercised for a period of five years from
the Grant Date.
The FCA notifications in respect of
the above Option grants, made in accordance with the requirements
of the UK Market Abuse Regulation, are appended below.
Enquiries:
Ondine Biomedical
Inc.
|
|
Angelika Vance, Corporate
Communications
|
+001 (604) 838 2702
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
Aubrey Powell, Asha Chotai, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine Biomedical
Inc.
Ondine Biomedical Inc. is a Canadian life
science company innovating in the field of photodisinfection
therapies. Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection platform, in various stages of
development. Ondine's nasal photodisinfection technology is
approved in several jurisdictions under the brand name Steriwave®.
It has been awarded the CE mark and, in the US, has been granted
Qualified Infectious Disease Product designation and Fast Track
status by the FDA. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic
sinusitis, ventilator-associated pneumonia, burns, and other
indications.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
a)
|
Name
|
1. Carolyn
Cross
2. Nicolas
Loebel
3. Joseph P.
Errico
4. Jean
Charest
5. Craig
Tooman
6. Mike
Farrar
7. Jean
Duvall
8. Simon
Sinclair
9. Junaid
Bajwa
|
2.
|
Reason for the Notification
|
a)
|
Position/status
|
1. CEO
(PDMR)
2. President
(PDMR)
3. CFO
(PDMR)
4.
Non-executive Chair (PDMR)
5.
Non-executive Director (PDMR)
6.
Non-executive Director (PDMR)
7.
Non-executive Director (PDMR)
8. Chief
Medical Officer (PDMR)
9.
Non-executive Director (PDMR)
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Ondine Biomedical Inc.
|
b)
|
LEI
|
9845005B69E07CGF4A56
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a)
|
Description of the Financial
instrument, type of instrument
|
Options to subscribe for Common
Shares
|
Identification code
|
ISIN: CA68234M2058
|
b)
|
Nature of the transaction
|
Grant of options to subscribe for
common shares of no par value
|
c)
|
Price(s) and volume(s)
|
PDMR
|
Price(s)
|
Volume(s)
|
Caroyn Cross
|
Exercise price of 9p per
share
|
2,000,000
|
Nicolas Loebel
|
Exercise price of 9p per
share
|
3,500,000
|
JP Errico
|
Exercise price of 9p per
share
|
3,000,000
|
Jean Charest
|
Exercise price of 9p per
share
|
40,000
|
Craig Tooman
|
Exercise price of 9p per
share
|
25,000
|
Michael Farrar
|
Exercise price of 9p per
share
|
25,000
|
Jean Duvall
|
Exercise price of 9p per
share
|
25,000
|
Simon Sinclair
|
Exercise price of 9p per
share
|
150,000
|
Junaid Bajwa
|
Exercise price of 9p per
share
|
25,000
|
|
d)
|
Aggregated information:
·Aggregated volume
·Price
|
N/A
|
e)
|
Date of the transaction
|
25 January 2024
|
f)
|
Place of the transaction
|
Outside a trading venue
|